VIP and graft versus host disease: Studies also demonstrated that donor pDCs regulated GVHD activities by restricting donor T‐cell activation via vasoactive intestinal polypeptide (VIP)‐receptor signaling by mobilization with Flt‐3L, which was beneficial in the prevention and treatment of GVHD through pDCs.